N4 Pharma Plc (LON:N4P – Get Free Report) traded up 4.7% during mid-day trading on Wednesday . The company traded as high as GBX 0.45 ($0.01) and last traded at GBX 0.45 ($0.01). 717,440 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 2,219,572 shares. The stock had previously closed at GBX 0.43 ($0.01).
N4 Pharma Trading Up 4.7 %
The firm has a market capitalization of £1.92 million, a price-to-earnings ratio of -1.29 and a beta of -0.37. The firm’s 50-day moving average is GBX 0.55 and its 200 day moving average is GBX 0.60.
About N4 Pharma
RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.
N4 Pharma’s lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.
Read More
- Five stocks we like better than N4 Pharma
- What Are Some of the Best Large-Cap Stocks to Buy?
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- How to Find Undervalued Stocks
- The 3 Most Talked About Investments on WallStreetBets Right Now
- Best Stocks Under $10.00
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for N4 Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for N4 Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
